GENOMICS: Functional Consortium Is Established

Applied Genetics News,  April, 2001  

• E-mail
• Print
• Link

Deltagen, Inc. (1003 Hamilton Ave., Menlo Park, CA 94205; Fax: 650/752-0202; Website: www.deltagen.com, Email: info@deltagen.com) is a founding member of a new international functional consortium, called the Centre for Modeling Human Disease (CMHD), based at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital (Toronto, Ontario).

"This will provide us with access to additional gene function data and intellectual property that can complement and expand our products and intellectual property portfolio, says William Matthews, president and CEO of Deltagen. "The combined forces of this consortium will also provide us with new opportunities to advance our own drug-discovery efforts."

The CMHD is composed of a multidisciplinary core group in the fields of mouse genetics, molecular biology and bioinformatics. Over the next several years, the consortium, led by Janet Rossant, will generate mouse models that will undergo detailed physiological, histopathological and imaging testing and analysis. CMHD plans to use three complementary approaches to generation of mouse models: chemical mutagenesis by ethylnitrosourea (ENU), targeted deletion mutagenesis and gene trap mutagenesis.

Consortium members will have the right to access and utilize the mouse model systems, data and intellectual property arising from CMHD's research and development programs.

COPYRIGHT 2001 Business Communications Company, Inc.
COPYRIGHT 2001 Gale Group